ATG4B and neoplasm: Some ATG4B inhibitors identified to date have been tested in xenograft models of colorectal cancer cells, typically HCT-116 cells, and demonstrated a significant benefit in reducing tumour growth, in particular when combined with chemotherapeutic agents [93].